{
    "clinical_study": {
        "@rank": "65400", 
        "acronym": "QD", 
        "arm_group": [
            {
                "arm_group_label": "Prolensa (bromfenac 0.07%)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days.  Dosing will begin three days prior to surgery (Day  3), continue on the day of surgery and for 21 days after surgery."
            }, 
            {
                "arm_group_label": "Ilevro (nepafenac 0.3%)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days.  Dosing will begin three days prior to surgery (Day  3), continue on the day of surgery and for 21 days after surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate inflammation, visual acuity and macular thickness after treatment with\n      Prolensa vs Ilevro after cataract surgery."
        }, 
        "brief_title": "Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cataract", 
            "Retinal Edema", 
            "Inflammation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Inflammation", 
                "Cataract", 
                "Papilledema"
            ]
        }, 
        "detailed_description": {
            "textblock": "To investigate the clinical outcomes for inflammation, visual acuity and macular thickness\n      after treatment with Prolensa (bromfenac ophthalmic solution) 0.07% QD in subjects who have\n      undergone cataract extraction with posterior chamber intraocular lens implantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are male or female at least 18 years of age who require cataract surgery and no other\n             surgical procedures during the cataract surgery.\n\n          -  Agree not to have any other ocular surgical procedures in the study or fellow (non\n             study) eye within 15 days prior to the initiation of dosing with the test article or\n             throughout the duration of the study.\n\n          -  Have a Best Corrected Visual Acuity of 20/200 or better in either eye.\n\n          -  Are able to self administer test article (or have a caregiver available to instill\n             all doses of test article).\n\n        Exclusion Criteria:\n\n          -  Have known hypersensitivity to bromfenac, nepafenac, loteprednol or any component of\n             the test article (including \"procedural\" medications such as anesthetic and/or\n             fluorescein drops, dilating drops, etc.).\n\n          -  Have a known hypersensitivity to salicylates (i.e., aspirin) or NSAIDs (nonsteroidal\n             antiinflammatory drug).\n\n          -  Have intraocular inflammation (i.e., cells or flare in the anterior chamber as\n             measured on slit lamp examination) in study eye at screening visit.\n\n          -  Have a known blood dyscrasia or bone marrow suppression, a diagnosis of\n             uncontrolled/unstable peptic ulcer disease, inflammatory bowel disease, or ulcerative\n             colitis, or any uncontrolled/unstable pulmonary, cardiac, vascular, autoimmune,\n             hepatic, renal, or central nervous system disease.\n\n          -  Have used ocular, topical, or systemic NSAIDs or ocular, topical, or systemic\n             gentamicin, or cyclosporine ophthalmic emulsion within 7 days prior to initiation of\n             dosing with the test article or throughout the duration of study,with exception of\n             allowing patients on a stable dose of aspirin 81 mg daily or less.\n\n          -  Have used ocular prostaglandins within 30 days prior to initiation of dosing with\n             test article or throughout the duration of study.\n\n          -  Have active corneal pathology noted in the study eye at screening visit.  Active\n             corneal pathology is defined as corneal pathology that is non stable, or greater than\n             mild, or will compromise assessment of the safety or efficacy of treatment.\n             Superficial punctate keratitis in study eye.\n\n          -  Have any extraocular/intraocular inflammation in the study eye at screening visit\n             (blepharitis allowed if mild only, and no concurrent conjunctivitis or lid\n             erythema/edema) or ongoing, unresolved uveitis.\n\n          -  Have used topical, ocular, inhaled or systemic steroids within 14 days prior to\n             screening.\n\n          -  Have had radial keratotomy, corneal transplant, or corneal refractive surgery in the\n             study eye within the last two years.\n\n          -  Have a history of abuse of alcohol/drugs within six months prior to the screening\n             visit.\n\n          -  Are pregnant or nursing/lactating.\n\n          -  Have participated in any other study of an investigational drug or device within 30\n             days prior to randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847638", 
            "org_study_id": "MMT-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prolensa (bromfenac 0.07%)", 
                "description": "Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery", 
                "intervention_name": "Prolensa (bromfenac 0.07%)", 
                "intervention_type": "Drug", 
                "other_name": "bromfenac ophthalmic solution 0.07%"
            }, 
            {
                "arm_group_label": "Ilevro (nepafenac 0.3%)", 
                "description": "Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery", 
                "intervention_name": "Ilevro (nepafenac 0.3%)", 
                "intervention_type": "Drug", 
                "other_name": "nepafenac ophthalmic suspension 0.3%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bromfenac"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Retinal edema", 
            "Cataract", 
            "inflammation"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "mtoyos@toyosclinic.com", 
                "last_name": "Melissa Toyos, MD", 
                "phone": "615-327-4015"
            }, 
            "contact_backup": {
                "email": "mtoyos@toyosclinic.com", 
                "last_name": "Melissa Toyos, MD", 
                "phone": "6153274015"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37203"
                }, 
                "name": "Toyos Clinic"
            }, 
            "investigator": {
                "last_name": "Melissa Toyos, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery", 
        "other_outcome": {
            "description": "Change in Retinal Thickness", 
            "measure": "Retinal Thickness", 
            "safety_issue": "No", 
            "time_frame": "42 days +/- 7 days increase from baseline and prior data point will be measured at each visit"
        }, 
        "overall_contact": {
            "email": "mtoyos@toyosclinic.com", 
            "last_name": "Melissa Toyos, MD", 
            "phone": "6153274015"
        }, 
        "overall_official": {
            "affiliation": "Toyos Clinic", 
            "last_name": "Melissa Toyos, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the clinical outcomes for inflammation after treatment with Prolensa (bromfenac ophthalmic solution) 0.07% QD in subjects who have undergone cataract extraction with posterior chamber intraocular lens implantation. Biomicroscopy with slit lamp beam of 0.3 mm in width and 1.0 mm in height will be used to determine anterior cell and flare scores at each study visit.", 
            "measure": "Treatment of inflammation associated with cataract surgery", 
            "safety_issue": "No", 
            "time_frame": "42 days +/-7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847638"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Discover Vision Centers", 
            "investigator_full_name": "Melissa Toyos, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in ETDRS log MAR Visual Acuity", 
            "measure": "Visual Acuity", 
            "safety_issue": "No", 
            "time_frame": "42 days +/-7 days"
        }, 
        "source": "Discover Vision Centers", 
        "sponsors": {
            "collaborator": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Melissa Toyos, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}